HS
HS
  • Home
  • Our team
  • OUR SERVICES
  • OUR RESEARCH
  • NEWS
  • Contact Us
  • More
    • Home
    • Our team
    • OUR SERVICES
    • OUR RESEARCH
    • NEWS
    • Contact Us
  • Home
  • Our team
  • OUR SERVICES
  • OUR RESEARCH
  • NEWS
  • Contact Us

OUR RESEARCH

 The research team, Washington Institute of Clinical Research, has consistently dedicated itself to clinical research, emphasizing areas such as autoimmune diseases, neurologic diseases, cancer, and rare diseases. We use advanced methods of big data analysis to drive forward our research endeavors and contribute to medical advancements. 

PUBLICATIONS

MemTrax memory test for Alzheimer’s Disease

 

  1. Liu W, Yu L, Deng Q, Li Y, Lu P, Yang J, Chen F, Li F, Zhou X, Bergeron MF, Ashford JW, Xu Q. Toward digitally screening and profiling AD: A GAMLSS approach of MemTrax in China. Alzheimers Dement. 2023 Aug 31. doi: 10.1002/alz.13430. Epub ahead of print. PMID: 37654085.
  2. Zhao X, Dai S, Zhang R, Chen X, Zhao M, Bergeron MF, Zhou X, Zhang J, Zhong L, Ashford JW, Liu X. Using MemTrax memory test to screen for post-stroke cognitive impairment after ischemic stroke: a cross-sectional study. Front Hum Neurosci. 2023 Jul 17;17:1195220. doi: 10.3389/fnhum.2023.1195220. PMID: 37529406; PMCID: PMC10387538.
  3. Chen W, Lin C, Su F, Fang Y, Liu G, Chen YC, Zhou X, Yao X, Ashford CB, Li F, Ashford JW, Fu QL, Pei Z. Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers. J Alzheimers Dis. 2023;94(3):1093-1103. doi: 10.3233/JAD-230182. PMID: 37355900.
  4. Ashford JW, Schmitt FA, Bergeron MF, Bayley PJ, Clifford JO, Xu Q, Liu X, Zhou X, Kumar V, Buschke H, Dean M, Finkel SI, Hyer L, Perry G. Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. J Alzheimers Dis. 2022;87(1):305-315. doi: 10.3233/JAD-220211. PMID: 35431257.
  5. Liu X, Chen X, Zhou X, Shang Y, Xu F, Zhang J, He J, Zhao F, Du B, Wang X, Zhang Q, Zhang W, Bergeron MF, Ding T, Ashford JW, Zhong L. Validity of the MemTrax Memory Test Compared to the Montreal Cognitive Assessment in the Detection of Mild Cognitive Impairment and Dementia due to Alzheimer's Disease in a Chinese Cohort. J Alzheimers Dis. 2021;80(3):1257-1267. doi: 10.3233/JAD-200936. PMID: 33646151.
  6. Bergeron MF, Landset S, Zhou X, Ding T, Khoshgoftaar TM, Zhao F, Du B, Chen X, Wang X, Zhong L, Liu X, Ashford JW. Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment. J Alzheimers Dis. 2020;77(4):1545-1558. doi: 10.3233/JAD-191340. PMID: 32894241; PMCID: PMC7683062.
  7. Zhou X, Ashford JW. Advances in screening instruments for Alzheimer's disease. Aging Med (Milton). 2019 May 31;2(2):88-93. doi: 10.1002/agm2.12069. PMID: 31942517; PMCID: PMC6880670.

Autoimmune Disease

 

  1. Li HY, Jiang P, Xie Y, Liang B, Li L, Zhao C, Yue YX, Li HF. Criteria for Treatment Response in Myasthenia Gravis: Comparison Between Absolute Change and Improvement Percentage in Severity Scores. Front Neurol. 2022 Jun 2;13:880040. doi: 10.3389/fneur.2022.880040. PMID: 35720071; PMCID: PMC9201395.
  2. Han JL, Yue YX, Gao X, Xie YC, Hao HJ, Li HY, Yu XL, Li J, Duan RS, Li HF. Vitamin D Receptor Polymorphism and Myasthenia Gravis in Chinese Han Population. Front Neurol. 2021 Feb 9;12:604052. doi: 10.3389/fneur.2021.604052. PMID: 33633666; PMCID: PMC7900549.
  3. Yue YX, Gao X, Tang TP, Xie Y, Gu CK, Hao HJ, Li HY, Ding XJ, Song M, Guo SG, Li HF. Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients. J Neuroimmunol. 2021 Apr 15;353:577487. doi: 10.1016/j.jneuroim.2021.577487. Epub 2021 Jan 30. PMID: 33578311.
  4. Cai GM, Gao Z, Yue YX, Xie YC, Gao X, Hao HJ, Zhang XJ, Wang Q, Liang B, Li HF. Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort. J Clin Neurosci. 2019 Nov;69:31-37. doi: 10.1016/j.jocn.2019.08.079. Epub 2019 Aug 28. PMID: 31473094.
  5. Jiang P, Yue YX, Hong Y, Xie Y, Gao X, Gu CK, Hao HJ, Qin Y, Ding XJ, Song M, Li HF, Zhang X. IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population. Front Neurol. 2018 Jul 10;9:529. doi: 10.3389/fneur.2018.00529. PMID: 30042722; PMCID: PMC6048264.

Medical Bibliometrics and Big Data Analysis

  1. Wen Q, Cao L, Yang C, Xie Y. The Electrophysiological Features in X-Linked Charcot-Marie-Tooth Disease With Transient Central Nervous System Deficits. Front Neurol. 2018 Jun 27;9:461. doi: 10.3389/fneur.2018.00461. PMID: 30013503; PMCID: PMC6036262. 

DR. yANCHEN xIE'S pUBLICATIONS

  1. Li HY, Jiang P, Xie Y, Liang B, Li L, Zhao C, Yue YX, Li HF. Criteria for Treatment Response in Myasthenia Gravis: Comparison Between Absolute Change and Improvement Percentage in Severity Scores. Front Neurol. 2022 Jun 2;13:880040. doi: 10.3389/fneur.2022.880040. PMID: 35720071; PMCID: PMC9201395.
  2. Han JL, Yue YX, Gao X, Xie YC, Hao HJ, Li HY, Yu XL, Li J, Duan RS, Li HF. Vitamin D Receptor Polymorphism and Myasthenia Gravis in Chinese Han Population. Front Neurol. 2021 Feb 9;12:604052. doi: 10.3389/fneur.2021.604052. PMID: 33633666; PMCID: PMC7900549.
  3. Yue YX, Gao X, Tang TP, Xie Y, Gu CK, Hao HJ, Li HY, Ding XJ, Song M, Guo SG, Li HF. Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients. J Neuroimmunol. 2021 Apr 15;353:577487. doi: 10.1016/j.jneuroim.2021.577487.
  4. Cai GM, Gao Z, Yue YX, Xie YC, Gao X, Hao HJ, Zhang XJ, Wang Q, Liang B, Li HF. Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort. J Clin Neurosci. 2019 Nov;69:31-37. doi: 10.1016/j.jocn.2019.08.079. 
  5. Jiang P, Yue YX, Hong Y, Xie Y, Gao X, Gu CK, Hao HJ, Qin Y, Ding XJ, Song M, Li HF, Zhang X. IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population. Front Neurol. 2018 Jul 10;9:529. doi: 10.3389/fneur.2018.00529.
  6. Wen Q, Cao L, Yang C, Xie Y. The Electrophysiological Features in X-Linked Charcot-Marie-Tooth Disease With Transient Central Nervous System Deficits. Front Neurol. 2018 Jun 27;9:461. doi: 10.3389/fneur.2018.00461.
  7. Aguilo-Seara G, Xie Y, Sheehan J, Kusner LL, Kaminski HJ. Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity. Cytokine. 2017 Aug; 96:279-285. doi: 10.1016/j.cyto.2017.05.008. 
  8. Xie Y, Li HF, Sun L, Kusner LL, Wang S, Meng Y, Zhang X, Hong Y, Gao X, Li Y, Kaminski HJ. The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis. Front Neurol. 2017;8:230. doi: 10.3389/fneur.2017.00230.
  9. Yang HW, Xie Y , Zhao Y, Sun L, Zhu X, Wang S, Zhang YQ, Lei P, Meng Y. TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis. Medicine (Baltimore). 2017 May; 96(20): e6798. doi: 10.1097/MD.0000000000006798. 
  10. Yang HW, Lei P, Xie YC, Han ZL, Li D, Wang SH, Sun ZL. Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population. Cancer Gene Ther. 2017 Apr 21. doi: 10.1038/cgt.2017.13.
  11. Zhang X, Ding XJ, Wang Q, Yue YX, Xie Y, Hao HJ, Liang B, Zhang XJ, Song M, Gao Z, Jiang P, Qin Y, Li HF. Rs3761389 polymorphism in autoimmune regulator (AIRE) gene is associated with susceptibility of myasthenia gravis in Chinese patients. J Clin Neurosci.2017 Mar 2. pii: S0967-5868(16)31368-6. doi: 10.1016/j.jocn.2017.02.049. 
  12. Li HF, Xie Y, Hong Y. Letter re: International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2017;88(5):505.
  13. Li HF, Hong Y, Zhang X, Xie Y, Skeie GO, Hao HJ, Gilhus NE, Liang B, Yue YX, Zhang XJ, Gao X,Wang Q, Gao Z, Ding XJ, Song M. Gene Polymorphisms for Both Auto-antigen and Immune-Modulating Proteins Are Associated with the Susceptibility of Autoimmune Myasthenia Gravis. Mol Neurobiol.2016 Aug 8. 
  14. Xie Y, Meng Y, Li HF, Hong Y, Sun L, Zhu X, Yue YX, Gao X, Wang S, Li Y, Kusner LL, Kaminski HJ. GRgene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. Eur J Neurol.2016, 23:1372-1379. doi: 10.1111/ene.13040.
  15. Li HF, Xie Y, Yue YX. Myasthenia gravis: subgroup classifications. Lancet Neurol.2016; 15(4):355-356.
  16. Xie Y, Li HF, Jiang B, Li Y, Kaminski HJ, Kusner LL. Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients. Cytokine.2016; 78:44-46.
  17. Yue YX, Hong Y, Xie Y, Hao HJ, Sui Y, Gu CK, Zhang X, Gao X, Tang TP, Zhang XJ, Wang Q, Li HF. Association study between IL-17A and IL-17F gene polymorphism and myasthenia gravis in Chinese patients. Neurol Sci.2016, 37(1), 123-130.
  18. Sun L, Meng Y, Xie Y, Zhang H, Zhang Z, Wang X, Jiang B, Li W, Li Y, Yang Z(co-corresponding author). CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population. PLoS One.2014, 9(7): e101986. doi: 10.1371/journal.pone.0101986. eCollection 2014.
  19. Zhao Y, Xie Y, Zhu X, Wang H, Li Y, Li J. Transient, recurrent, white matter lesions in x-linked Charcot-Marie-tooth disease with novel mutation of gap junction protein beta 1 gene in China: a case report. BMC Neurol.2014, 14(1):156. doi: 10.1186/s12883-014-0156-5.
  20. Hong Y, Hao HJ, Xie YC, Wang Q, Li HF. Effect of storage conditions and freeze/thaw cycles on serum and plasma levels of anti-acetylcholine receptor (AChR) antibody. Clin Chem Lab Med. 2014, 10:1-3. doi: 10.1515/cclm-2013-1021.
  21. Li HF, Gao X, Xie YC. Recommendations for myasthenia gravis clinical trials. Muscle Nerve.2013, 47(1):144-145. doi: 10.1002/mus.23670. 
  22. Yang H, Hao J, Peng X, Simard AR, Zhang M, Xie Y, Wang S. The association of HLA-DQA1*0401 and DQB1*0604 with thymomatous myasthenia gravis in northern Chinese patients. J Neurol Sci. 2012, 312(1-2):57-61.
  23. Li HF, Xie YC. Does increased serum IL-17 level imply its pathogenic role in myasthenia gravis? Muscle Nerve. 2012, 45(1):147. doi: 10.1002/mus.22272.
  24. Xie YC, Qu Y, Sun L, Li HF, Zhang H, Shi HJ, Jiang B, Zhao Y, Qiao SS, Wang SH, Wang DX. Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population. J Clin Neurosci. 2011，18(11):1524-1527.
  25. Li HF, Xie YC. Guillian-Barre syndrome. Lancet Neurol. 2008, 7(12):1081-1082. 
  26. Wang B, Xie YC, Yang Z, Peng D, Wang J, Zhou S, Li S, Ma X. Lack of an association between Alzheimer's Disease and the Cystatin C (CST3) Gene G73A Polymorphism in Mainland Chinese. Dement Geriatr Cogn Disord. 2008, 25(5):461-464. 
  27. Wang B, Zhou S, Yang Z, Xie YC, Wang J, Zhang P, Lv Z, Zheng C, Ma X. Genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A and Saitohin Q7R polymorphisms with Alzheimer's disease. J Neurol Sci. 2008, 270(1-2):148-151. 
  28. Lin Y, Zheng JY, Jin YH, Xie YC, Jin ZB.Trinucleotide expansions in the SCA7 gene in a large family with spinocerebellar ataxia and craniocervical dystonia. Neurosci Lett. 2008, 434(2):230-233.
  29. Wang B, Tan S, Yang Z, Xie YC, Wang J, Zhou S, Li S, Zheng C, Ma X. Association between Alzheimer's disease and the NOS3 gene Glu298Asp polymorphism in Chinese. J Mol Neurosci. 2008, 34(2):173-176. 
  30. Wang B, Wang J, Zhou S, Tan S, He X, Yang Z, Xie YC, Li S, Zheng C, Ma X. The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neurol Sci. 2008, 268(1-2):172-175.
  31. Wang BB, Jin F, Xie YC, Tang Y, Kan R, Zheng CG, Yang Z, Wang L. Association analysis of NAD(P)H: quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer’s disease. Neurosci Lett. 2006, 409(3):179-181.
  32. Li HF, Xie YC. Posterior Column Involvement in Miller Fisher Syndrome or Dorsal Root Ganglion Neuronopathy. AJNR Am J Neuroradiol. 2005, 26(7):1881-1882. 

DR. Ryan Reyes' pUBLICATIONS

  1. Bai H, Padron AS, Deng Y, Liao YJ, Murray CJ, Ontiveros C, Kari SJ, Kancharla A, Kornepati AVR, Garcia M, Reyes RM, Gupta HB, Conejo-Garcia JR, Curiel T. Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects. J Immunother Cancer. 2023 Feb;11(2):e004871. doi: 10.1136/jitc-2022-004871. PMID: 36759012; PMCID: PMC9923271.
  2. Garcia MG, Deng Y, Murray C, Reyes RM, Padron A, Bai H, Kancharla A, Gupta H, Shen-Orr S, Curiel TJ. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging Cancer. 2022 Mar;3(1):68-83. doi: 10.1002/aac2.12045. Epub 2022 Feb 25. PMID: 36876140; PMCID: PMC9980712.
  3. Reyes RM, Zhang C, Deng Y, Ji N, Mukherjee N, Padron AS, Clark CA, Svatek RS, Curiel TJ. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. Oncoimmunology. 2021 Nov 22;10(1):2006529. doi: 10.1080/2162402X.2021.2006529. PMID: 34858732; PMCID: PMC8632314.
  4. Deng Y, Reyes RM, Zhang C, Conejo-Garcia J, Curiel TJ. Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances. J Cell Immunol. 2021;3(6):387-396. doi: 10.33696/immunology.3.122. PMID: 36968176; PMCID: PMC10035448.
  5. Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AVR, Kancharla A, Sun X, Deng Y, Wu B, Vadlamudi R, Li R, Svatek RS, Curiel TJ. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021 Mar;10(6):2137-2152. doi: 10.1002/cam4.3739. Epub 2021 Feb 24. PMID: 33626233; PMCID: PMC7957205.
  6. Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu ZJ, Ramamurthy C, Dennett R, Curiel TJ, Svatek RS. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer. 2021 Mar;9(3):e001941. doi: 10.1136/jitc-2020-001941. PMID: 33653802; PMCID: PMC7929866.
  7. Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. J Immunother Cancer. 2021 Apr;9(4):e002051. doi: 10.1136/jitc-2020-002051. PMID: 33849925; PMCID: PMC8051418.
  8. Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ, Gelfond JA, Curiel TJ, Svatek RS. γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunol Res. 2021 Dec;9(12):1491-1503. doi: 10.1158/2326-6066.CIR-21-0285. Epub 2021 Oct 4. PMID: 34607803; PMCID: PMC8691423.
  9. Reyes RM, Rios E, Barney S, Hugen CM, Michalek JE, Lotan Y, Messing EM, Svatek RS. A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2021;7(3):285-295. doi: 10.3233/blc-201535. PMID: 34621937; PMCID: PMC8494135.
  10. Drerup JM, Deng Y, Pandeswara SL, Padrón ÁS, Reyes RM, Zhang X, Mendez J, Liu A, Clark CA, Chen W, Conejo-Garcia JR, Hurez V, Gupta H, Curiel TJ. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Res. 2020 Nov 15;80(22):5063-5075. doi: 10.1158/0008-5472.CAN-20-0002. Epub 2020 Sep 18. PMID: 32948605; PMCID: PMC7669742.
  11. Rios EM, Parma MA, Fernandez RA, Clinton TN, Reyes RM, Kaushik D, Pruthi D, Mansour AM, Mukherjee N, Gelfond J, Wheeler KM, Svatek RS. Urinary Diversion Disparity Following Radical Cystectomy for Bladder Cancer in the Hispanic Population. Urology. 2020 Mar;137:66-71. doi: 10.1016/j.urology.2019.12.017. Epub 2019 Dec 27. PMID: 31883879; PMCID: PMC7063861.

Copyright © 2023 Healsan - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept